| Drug Name |
Brivaracetam |
| Drug ID |
BADD_D00297 |
| Description |
Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam [A19184]. It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 [L760]. |
| Indications and Usage |
Used as adjunctive therapy for partial-onset seizures in patients 16 years of age or older. |
| Marketing Status |
approved; investigational |
| ATC Code |
N03AX23 |
| DrugBank ID |
DB05541
|
| KEGG ID |
D08879
|
| MeSH ID |
C482793
|
| PubChem ID |
9837243
|
| TTD Drug ID |
D0CT4D
|
| NDC Product Code |
16812-009; 36998-0118; 50474-670; 50474-770; 50474-970; 52076-6268; 28877-0118; 71666-007; 50474-370; 82608-003; 50474-570; 64220-214; 69037-0055; 50474-470; 69766-031; 50474-870 |
| UNII |
U863JGG2IA
|
| Synonyms |
brivaracetam | 2-(2-oxo-4-propylpyrrolidin-1-yl)butanamide | (2S)-2-((4R)-2-oxo-4-propylpyrrolidin-1-yl)butanamide | 1-pyrrolidineacetamide, alpha-ethyl-2-oxo-4-propyl-, (alphaS,4R)- | UCB 34714 | UCB34714 | UCB-34714 | Briviact |
